Leucine-rich repeat kinase 2 modulates cyclooxygenase 2 and the inflammatory response in idiopathic and genetic Parkinson's disease
Open accessAbstract
Inflammatory mechanisms are activated in aging and late-onset neurodegenerative diseases, such as Parkinson's disease (PD). Mutations in leucine-rich repeat kinase 2 (LRRK2) contribute to both idiopathic and familial forms of PD. Here, we investigated the involvement of LRRK2 in inflammatory pathways using primary dermal fibroblasts from patients with 2 common mutations in LRRK2 (G2019S and R1441G), idiopathic PD and age-matched healthy individuals. Basal cyclooxygenase (COX)-2 RNA levels were very high in the fibroblasts of all patients. Remarkably, LRRK2 silencing experiments significantly reduced basal COX-2 levels and COX-2 induction after a pro-inflammatory stimulus. Additionally, in samples from patients with the R1441G mutation and with idiopathic PD, we found a prominent cytoplasmic re-distribution of human antigen R, a protein that, among others, stabilizes COX-2 RNA. Furthermore, the response to lipopolysaccharide was defective in these 2 groups, which showed weak induction of pro-inflammatory cytokines and reduced NFκB transcriptional activation. In summary, we describe multiple defects in inflammatory pathways in which LRRK2 appears to be critically involved. Further studies are required to establish the therapeutic implications of inflammatory dysregulation in the pathophysiology of Parkinson's disease.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Epidermal cells obtained from PD patients with the LRRK2-G2019S mutation showed a blunted response to LPS treatment compared to control cells.
“In agreement with our findings, a recent study reported that epidermal cells obtained from PD patients with the LRRK2-G2019S mutation showed a blunted response to LPS treatment compared to control cells (65).”
From LRRK2 mediates microglial neurotoxicity via NFATc2 in rodent models of synucleinopathies (2020) · cites this paper as [65]
Cites
Hypothalamic programming of systemic ageing involving IKK-β, NF-κB and GnRH
Zhang, G., Li, J., Purkayastha, S., Tang, Y., Zhang, H., Yin, Y., Li, B., Liu, G., & Cai, D. (2013) · Nature · doi:10.1038/nature12143 · Cited by 834 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Inflammation is genetically implicated in Parkinson’s disease
Dzamko, N., Geczy, C. L., & Halliday, G. M. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2014.10.028 · Cited by 222 · see citing works
LRRK2 mediates microglial neurotoxicity via NFATc2 in rodent models of synucleinopathies
Kim, C., Beilina, A., Smith, N., Li, Y., Kim, M., Kumaran, R., Kaganovich, A., Mamais, A., Adame, A., Iba, M., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay0399 · Cited by 79 · see citing works
- Authors
- Lopez de Maturana, R., Aguila, J. C., Sousa, A., Vazquez, N., del Rio, P., Aiastui, A., Gorostidi, A., Lopez de Munain, A., & Sanchez-Pernaute, R.
- Affiliations
- Biogipuzkoa Health Research Institute (ES)
- Venue
- Neurobiology of Aging
- Publisher
- Elsevier BV
- Published
- 2014-05
- Volume
- 35
- Issue
- 5
- Pages
- 1116-1124
- ISSN
- 0197-4580 (ISSN-L)
- OpenAlex
- W2083760444
- Cited by
- 38
- References
- 1
- Citations by year
- 2026: 2 · 2023: 1 · 2022: 2 · 2021: 2 · 2020: 5 · 2019: 2 · 2018: 3 · 2017: 3 · 2016: 8 · 2015: 2 · 2014: 7
- FWCI
- 3.60
- Type
- journal article
- Language
- en
- Open access
- green
- zenodo.org
- Licence
- Locations
- Neurobiology of Aging (publishedVersion)
- PubMed (publishedVersion)
- Zenodo (CERN European Organization for Nuclear Research) (submittedVersion, other-oa)
- Funders
- Departments of Industry (S-PE10IB04)
- Education of the Basque Government (EC2011/47)
- European Commission (DDPDGENES RR 278871-2)
- ISCIII, Spanish Ministry of Economy and Competitiveness, and Health Research Biodonostia Institute (CA00/01506)
- FPI (BES-2009-028305)
- Topics
- Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nuclear Receptors and Signaling
- Keywords
- LRRK2, cyclooxygenase-2, Parkinson's disease, neuroinflammation, LRRK2 mutations, dermal fibroblasts, HuR, lipopolysaccharide response, inflammatory cytokines, NF-κB activation, familial Parkinson's disease
- MeSH terms
- Leucine-Rich Repeat Serine-Threonine Protein Kinase-2, Aged, Aged, 80 and over, Cells, Cultured, Fibroblasts, Humans, Inflammation, Middle Aged, Mutation, Parkinson Disease, RNA, Transcriptional Activation, NF-kappa B, Protein Serine-Threonine Kinases, Cyclooxygenase 2, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review